Acute myeloid leukemia: focus on novel therapeutic strategies.

A pre-specified subset analysis by cytogenetic risk category did show a highly significant benefit of induction GO in patients with favorable risk cytogenetics (79% versus 51% overall survival, P = 0.001).

also in 132,142 other papers

54%, P = 0.002), and this advantage was more pronounced in those aged 60–65 with a trend towards significance (CR 73% vs. 51%, P = 0.07).

also in 2,760 other papers

CR rates were higher than historical controls across the entire cohort (85% versus 72%, P = 0.01), and subset analyses showed a trend toward improvements in CR rate for patients with abnormalities of chromosomes 5 or 7 or FLT3 mutations. 33 Efforts to capitalize on known molecular aberrations in specific subtypes of AML include trials of imatinib in c-KIT mutated AML and FLT3 inhibitors in FLT3- mutant AML. 23 Strategies to Develop Less Toxic Induction Regimens Intensive induction chemotherapy is recommended for all patients who are fit to tolerate it.

also in 53,322 other papers